Suresh Kumar Kali
Bharathidasan University, India
Received: January 11,2022; Accepted: January 14,2022; Published:February 07,2022
Scientific Tracks Abstracts: J Infect Dis Preve Med
COVID-19 exhibits a global health threat among the elderly and the population with underlying health conditions. During infection, the host’s innate immune response acts as a frontline of defense by releasing cytokines such as type I interferon (IFN α and β) thereby initiating antiviral activity. However, this particular interferon response is interrupted by factors such as SARS-CoV-2 non-structural proteins, aging, diabetes and germ-line errors eventually making the host more susceptible to illness. Thus, the deficiency of type I IFN leads to poor innate immune responses in the host against SARS-CoV-2 infection, eventually leading to severe illness. Therefore, enhancing the host’s innate immune response by administering type I IFN could be a key to prevent the host from COVID- 19 severity. Several viral diseases primarily target the innate immune response to replicate and progress in the host. Intriguingly, COVID-19 severity was associated with a significantly low innate immune response. IFN β monotherapy would be an effective early-stage treatment option to prevent COVID-19 severity. For instance, SNG001, an IFN β product, is in phase 3 clinical trial against COVID-19 and its final data will reveal the efficiency of IFN β monotherapy. We evaluated here the importance of the innate immune response during SARS-CoV-2 infection and the molecular mechanism of IFN β-mediated antiviral activity against SARS- CoV- 2 infection and concluded that the IFN β monotherapy as an attractive potent treatment option against SARSCoV- 2. Therefore, IFN β monotherapy-mediated enhancement of innate immune response could be a key component in future strategies to prevent large-scale viral disease outbreaks
Suresh Kumar Kali has his expertise in infection immunology and passionate in improving translational research. His open and contextual reviews based on constructive evidence creates new pathways for improving therapeutics. He has articulated this review after years of experience in research and evaluation in education institutions. This review is peer-reviewed and published on international journal.